Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piper Jaffray Healthcare Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

J&J/DePuy ASR hip: Investigational device exemption filing for the Articular Surface Replacement less-invasive hip system will be submitted to FDA this year, leading to a U.S. launch in 2007, J&J Worldwide Chairman-Medical Devices & Diagnostics Michael Dormer reports at a Jan. 27 session of the Piper Jaffray Healthcare Conference in New York. A European debut is slated for this quarter. Targeting a $500 mil. market, the device "provides excellent function with less damage to the natural bone structure" and "permits total hip replacement in later years should the need ever arise," the exec explains. J&J also is readying the Proxima conservative hip replacement system, preparing to begin European trials by Q2 with hopes for a 510(k) submission by Q1 2005. Proxima is designed to support minimally-invasive surgical techniques. A ceramic-on-ceramic hip bearing already available outside the U.S. is on track for U.S. approval in the second half of 2004...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT019724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel